Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Fernanda Musa,Bhavana Pothuri,Stephanie V Blank,Huichung T Ling,James L Speyer,John Curtin,Leslie Boyd,Xiaochun Li,Judith D Goldberg,Franco Muggia,Amy Tiersten

Gynecologic Oncology（2017）

Cited 28|Views25
No score
Abstract
•Combination bevacizumab and irinotecan have anti-tumor activity in recurrent ovarian cancer•Combination of bevacizumab and irinotecan has acceptable toxicity.•Patients were heavily pre-treated and had received prior topotecan and bevacizumab.
More
Translated text
Key words
Clinical trial,Phase II,Ovarian cancer,Bevacizumab,Irinotecan
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined